keyword
MENU ▼
Read by QxMD icon Read
search

Aspirin colorectal cancer

keyword
https://www.readbyqxmd.com/read/28448072/evaluation-of-ptgs2-expression-pik3ca-mutation-aspirin-use-and-colon-cancer-survival-in-a-population-based-cohort-study
#1
Ronan T Gray, Marie M Cantwell, Helen G Coleman, Maurice B Loughrey, Peter Bankhead, Stephen McQuaid, Roisin F O'Neill, Kenneth Arthur, Victoria Bingham, Claire McGready, Anna T Gavin, Chris R Cardwell, Brian T Johnston, Jacqueline A James, Peter W Hamilton, Manuel Salto-Tellez, Liam J Murray
OBJECTIVES: The association between aspirin use and improved survival after colorectal cancer diagnosis may be more pronounced in tumors that have PIK3CA mutations or high PTGS2 expression. However, the evidence of a difference in association by biomarker status lacks consistency. In this population-based colon cancer cohort study the interaction between these biomarkers, aspirin use, and survival was assessed. METHODS: The cohort consisted of 740 stage II and III colon cancer patients diagnosed between 2004 and 2008...
April 27, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/28434157/general-practitioner-attitudes-towards-prescribing-aspirin-to-carriers-of-lynch-syndrome-findings-from-a-national-survey
#2
Samuel G Smith, Robbie Foy, Jennifer McGowan, Lindsay C Kobayashi, John Burn, Karen Brown, Lucy Side, Jack Cuzick
A dose non-inferiority study comparing 100 mg, 300 mg and 600 mg of aspirin for cancer prevention among Lynch Syndrome carriers is underway (Colorectal Adenoma/Carcinoma Prevention Programme trial 3, CaPP3). To guide implementation of the findings, we investigated general practitioner (GP) attitudes towards aspirin prescribing for Lynch Syndrome carriers. We surveyed 1007 UK GPs (9.6% response rate). Using a within-subjects design, GPs read a statement on harms and benefits of aspirin and indicated their willingness to prescribe aspirin at three doses (100 mg, 300 mg, 600 mg)...
April 22, 2017: Familial Cancer
https://www.readbyqxmd.com/read/28431950/postoperative-adjuvant-chemotherapy-is-associated-with-a-lower-incidence-of-colorectal-adenomas-in-patients-with-previous-colorectal-cancer
#3
Hee Seung Lee, Sung Bae Kim, Hyun Jung Lee, Soo Jung Park, Sung Pil Hong, Jae Hee Cheon, Won Ho Kim, Tae Il Kim
BACKGROUND AND AIMS: The effects of chemotherapeutic agents on the development of colorectal adenomas in patients with previous colorectal cancer (CRC) are not defined. Therefore, we evaluated the potential effect of adjuvant chemotherapy on the incidence of colorectal adenomas in patients with previous CRC. METHODS: We selected patients with low-risk stage II CRC with or without postoperative 5-fluorouracil-based adjuvant chemotherapy to reduce selection bias. Among 1808 patients with stage II CRC who underwent colonoscopic surveillance after curative resection of CRC between 2006 and 2013, 192 patients were retrospectively enrolled in this study after matching for age and sex...
April 18, 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28406723/aspirin-use-and-colorectal-cancer-survival-according-to-tumor-cd274-programmed-cell-death-1-ligand-1-expression-status
#4
Tsuyoshi Hamada, Yin Cao, Zhi Rong Qian, Yohei Masugi, Jonathan A Nowak, Juhong Yang, Mingyang Song, Kosuke Mima, Keisuke Kosumi, Li Liu, Yan Shi, Annacarolina da Silva, Mancang Gu, Wanwan Li, NaNa Keum, Xuehong Zhang, Kana Wu, Jeffrey A Meyerhardt, Edward L Giovannucci, Marios Giannakis, Scott J Rodig, Gordon J Freeman, Daniel Nevo, Molin Wang, Andrew T Chan, Charles S Fuchs, Reiko Nishihara, Shuji Ogino
Purpose Blockade of the programmed cell death 1 (PDCD1, PD-1) immune checkpoint pathway can improve clinical outcomes in various malignancies. Evidence suggests that aspirin (a widely used nonsteroidal anti-inflammatory drug) not only prolongs colorectal cancer survival, but can also activate T cell-mediated antitumor immunity and synergize with immunotherapy through inhibition of prostaglandin E2 production. We hypothesized that the survival benefit associated with aspirin might be stronger in colorectal carcinoma with a lower CD274 (PDCD1 ligand 1, PD-L1) expression level that resulted in lower signaling of the immune checkpoint pathway...
April 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28381238/homozygous-germ-line-mutation-of-the-pms2-mismatch-repair-gene-a-unique-case-report-of-constitutional-mismatch-repair-deficiency-cmmrd
#5
N C Ramchander, N A J Ryan, E J Crosbie, D G Evans
BACKGROUND: Constitutional mismatch repair deficiency syndrome results from bi-allelic inheritance of mutations affecting the key DNA mismatch repair genes: MLH1, MSH2, MSH6 or PMS2. Individuals with bi-allelic mutations have a dysfunctional mismatch repair system from birth; as a result, constitutional mismatch repair deficiency syndrome is characterised by early onset malignancies. Fewer than 150 cases have been reported in the literature over the past 20 years. This is the first report of the founder PMS2 mutation - NM_000535...
April 5, 2017: BMC Medical Genetics
https://www.readbyqxmd.com/read/28376458/health-benefits-and-cost-effectiveness-of-asymptomatic-screening-for-hypertension-and-high-cholesterol-and-aspirin-counseling-for-primary-prevention
#6
Steven P Dehmer, Michael V Maciosek, Amy B LaFrance, Thomas J Flottemesch
PURPOSE: Our aim was to update estimates of the health and economic impact of clinical services recommended for the primary prevention of cardiovascular disease (CVD) for the comparative rankings of the National Commission on Prevention Priorities, and to explore differences in outcomes by sex and race/ethnicity. METHODS: We used a single, integrated, microsimulation model to generate comparable results for 3 services recommended by the US Preventive Services Task Force: aspirin counseling for the primary prevention of CVD and colorectal cancer, screening and treatment for lipid disorders (usually high cholesterol), and screening and treatment for hypertension...
January 2017: Annals of Family Medicine
https://www.readbyqxmd.com/read/28371181/incidence-of-intracranial-bleeds-in-new-users-of-low-dose-aspirin-a-cohort-study-using-the-health-improvement-network
#7
Lucía Cea Soriano, David Gaist, Montse Soriano-Gabarró, Luis A García Rodríguez
BACKGROUND: Low-dose aspirin protects against ischemic cardiovascular (CV) events as well as colorectal cancer (CRC). However, low-dose aspirin may be associated with a small increased risk of intracranial bleeds (ICB). OBJECTIVES: To obtain incidence rates of ICB overall and by patient subgroups among new users of low-dose aspirin. PATIENTS/METHODS: Using The Health Improvement Network (THIN) UK primary care database (2000-2012), we identified a cohort of new users of low-dose aspirin aged 40-84 years (N=199,079; mean age at start of follow-up, 63...
March 31, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28359968/the-mortality-reducing-effect-of-aspirin-in-colorectal-cancer-patients-interpreting-the-evidence
#8
REVIEW
Martine A Frouws, Myrthe P P van Herk-Sukel, Huub A Maas, Cornelis J H Van de Velde, Johanneke E A Portielje, Gerrit-Jan Liefers, Esther Bastiaannet
In 1971 the first study appeared that suggested a relationship between aspirin and cancer. Currently publications on the subject of aspirin and cancer are numerous, with both a beneficial effect of aspirin on cancer incidence and a beneficial effect on cancer survival. This review focusses on the relation between the use of aspirin and improved survival in colorectal cancer patients. Various study designs have been used, with the main part being observational studies and post hoc meta-analyses of cancer outcomes in cardiovascular prevention trials...
February 20, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28350995/the-difference-in-association-between-aspirin-use-and-other-thrombocyte-aggregation-inhibitors-and-survival-in-patients-with-colorectal-cancer
#9
M A Frouws, E Rademaker, E Bastiaannet, M P P van Herk-Sukel, V E Lemmens, C J H Van de Velde, J E A Portielje, G J Liefers
BACKGROUND: Several studies have suggested that the association between aspirin and improved cancer survival is mediated through the mechanism of aspirin as thrombocyte aggregation inhibitors (TAI). The aim of this study was to provide epidemiological evidence for this mechanism assessing the association between overall survival and the use of aspirin and non-aspirin TAI in patients with colorectal cancer. METHODS: In this observational study, data from the Netherlands Comprehensive Cancer Organisation were linked to PHARMO Database Network...
March 25, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28290628/aspirin-for-the-prevention-of-cardiovascular-disease-and-colorectal-cancer-new-recommendations-from-the-uspstf
#10
Douglas K Owens
No abstract text is available yet for this article.
February 15, 2017: American Family Physician
https://www.readbyqxmd.com/read/28267439/mechanisms-of-colitis-accelerated-colon-carcinogenesis-and-its-prevention-with-the-combination-of-aspirin-and-curcumin-transcriptomic-analysis-using-rna-seq
#11
Yue Guo, Zheng-Yuan Su, Chengyue Zhang, John M Gaspar, Rui Wang, Ronald P Hart, Michael P Verzi, Ah-Ng Tony Kong
Colorectal cancer (CRC) remains the leading cause of cancer-related death in the world. Aspirin (ASA) and curcumin (CUR) are widely investigated chemopreventive candidates for CRC. However, the precise mechanisms of their action and their combinatorial effects have not been evaluated. The purpose of the present study was to determine the effect of ASA, CUR, and their combination in azoxymethane/dextran sulfate sodium (AOM/DSS)-induced colitis-accelerated colorectal cancer (CAC). We also aimed to characterize the differential gene expression profiles in AOM/DSS-induced tumors as well as in tumors modulated by ASA and CUR using RNA-seq...
March 3, 2017: Biochemical Pharmacology
https://www.readbyqxmd.com/read/28219002/molecular-testing-for-gastrointestinal-cancer
#12
REVIEW
Hye Seung Lee, Woo Ho Kim, Yoonjin Kwak, Jiwon Koh, Jeong Mo Bae, Kyoung-Mee Kim, Mee Soo Chang, Hye Seung Han, Joon Mee Kim, Hwal Woong Kim, Hee Kyung Chang, Young Hee Choi, Ji Y Park, Mi Jin Gu, Min Jin Lhee, Jung Yeon Kim, Hee Sung Kim, Mee-Yon Cho
With recent advances in molecular diagnostic methods and targeted cancer therapies, several molecular tests have been recommended for gastric cancer (GC) and colorectal cancer (CRC). Microsatellite instability analysis of gastrointestinal cancers is performed to screen for Lynch syndrome, predict favorable prognosis, and screen patients for immunotherapy. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor has been approved in metastatic CRCs with wildtype RAS (KRAS and NRAS exon 2-4). A BRAF mutation is required for predicting poor prognosis...
March 2017: Journal of Pathology and Translational Medicine
https://www.readbyqxmd.com/read/28184026/identification-of-tmem208-and-pqlc2-as-reference-genes-for-normalizing-mrna-expression-in-colorectal-cancer-treated-with-aspirin
#13
Yuanyuan Zhu, Chao Yang, Mingjiao Weng, Yan Zhang, Chunhui Yang, Yinji Jin, Weiwei Yang, Yan He, Yiqi Wu, Yuhua Zhang, Guangyu Wang, Riju James RajkumarEzakiel Redpath, Lei Zhang, Xiaoming Jin, Ying Liu, Yuchun Sun, Ning Ning, Yu Qiao, Fengmin Zhang, Zhiwei Li, Tianzhen Wang, Yanqiao Zhang, Xiaobo Li
Numerous evidences indicate that aspirin usage causes a significant reduction in colorectal cancer. However, the molecular mechanisms about aspirin preventing colon cancer are largely unknown. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) is a most frequently used method to identify the target molecules regulated by certain compound. However, this method needs stable internal reference genes to analyze the expression change of the targets. In this study, the transcriptional stabilities of several traditional reference genes were evaluated in colon cancer cells treated with aspirin, and also, the suitable internal reference genes were screened by using a microarray and were further identified by using the geNorm and NormFinder softwares, and then were validated in more cell lines and xenografts...
April 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28181993/bariatric-surgery-prior-to-index-screening-colonoscopy-is-associated-with-a-decreased-rate-of-colorectal-adenomas-in-obese-individuals
#14
Dmitriy Kedrin, Shaan-Chirag Chandrahas Gandhi, Molly Wolf, Jatin Roper, Omer Yilmaz, Kathleen Corey, Hamed Khalili, Fatima Cody Stanford, Manish Gala
OBJECTIVES: Obesity is an important risk factor for the development of colorectal cancer (CRC). Although the impact of bariatric surgery on CRC is conflicting, its impact on precursor lesions is unknown. The aim of this study was to determine whether bariatric surgery before index screening colonoscopy is associated with decreased development of colorectal adenomas. METHODS: We performed a retrospective cohort study of bariatric surgery patients who had undergone index, screening colonoscopy at an academic center from 2001 to 2014...
February 9, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/28154202/aspirin-induced-chemoprevention-and-response-kinetics-are-enhanced-by-pik3ca-mutations-in-colorectal-cancer-cells
#15
Timothy J Zumwalt, Dominik Wodarz, Natalia L Komarova, Shusuke Toden, Jacob Turner, Jacob Cardenas, John Burn, Andrew T Chan, C Richard Boland, Ajay Goel
This study was designed to determine how aspirin influences the growth kinetics and characteristics of cultured colorectal cancer cells that harbor a variety of different mutational backgrounds, including PIK3CA- and KRAS-activating mutations, and the presence or absence of microsatellite instability. Colorectal cancer cell lines (HCT116, HCT116 + Chr3/5, RKO, SW480, HCT15, CACO2, HT29, and SW48) were treated with pharmacologically relevant doses of aspirin (0.5-10 mmol/L) and evaluated for proliferation and cell-cycle distribution...
March 2017: Cancer Prevention Research
https://www.readbyqxmd.com/read/28143522/aspirin-intervention-for-the-reduction-of-colorectal-cancer-risk-aspired-a-study-protocol-for-a-randomized-controlled-trial
#16
David A Drew, Samantha M Chin, Katherine K Gilpin, Melanie Parziale, Emily Pond, Madeline M Schuck, Kathleen Stewart, Meaghan Flagg, Crystal A Rawlings, Vadim Backman, Peter J Carolan, Daniel C Chung, Francis P Colizzo, Matthew Freedman, Manish Gala, John J Garber, Curtis Huttenhower, Dmitriy Kedrin, Hamed Khalili, Douglas S Kwon, Sanford D Markowitz, Ginger L Milne, Norman S Nishioka, James M Richter, Hemant K Roy, Kyle Staller, Molin Wang, Andrew T Chan
BACKGROUND: Although aspirin is recommended for the prevention of colorectal cancer, the specific individuals for whom the benefits outweigh the risks are not clearly defined. Moreover, the precise mechanisms by which aspirin reduces the risk of cancer are unclear. We recently launched the ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED) trial to address these uncertainties. METHODS/DESIGN: ASPIRED is a prospective, double-blind, multidose, placebo-controlled, biomarker clinical trial of aspirin use in individuals previously diagnosed with colorectal adenoma...
February 1, 2017: Trials
https://www.readbyqxmd.com/read/28139830/low-dose-aspirin-acetylates-cyclooxygenase-1-in-human-colorectal-mucosa-implications-for-the-chemoprevention-of-colorectal-cancer
#17
Paola Patrignani, Angela Sacco, Carlos Sostres, Annalisa Bruno, Melania Dovizio, Elena Piazuelo, Luigia Di Francesco, Annalisa Contursi, Mirco Zucchelli, Simone Schiavone, Stefania Tacconelli, Carlo Patrono, Angel Lanas
The mechanism of action of low-dose aspirin in the prevention of colorectal cancer (CRC) remains largely hypothetical. We aimed to compare the effects of low-dose aspirin (100 mg/day for 7 days) given to 40 individuals undergoing CRC screening on the extent of cyclooxygenase (COX)-1 acetylation at serine-529 (AceCOX-1), in blood platelets vs colorectal mucosa, at 7 (group 1) and 24 hours (group 2) after dosing. A significantly (P<0.01) lower %AceCOX-1 was detected in colonic and rectal mucosa (average 64%) vs platelets (average 75%) in both groups...
January 31, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28124492/helicobacter-pylori-infection-is-an-independent-risk-factor-of-early-and-advanced-colorectal-neoplasm
#18
Tae Jun Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim, Sun-Young Baek, Kyunga Kim, Sung Noh Hong
BACKGROUND: The role of Helicobacter pylori (H. pylori) in the development of colorectal neoplasm remains controversial. We examined the association between H. pylori infection and colorectal neoplasm in a large sample of healthy participants who underwent screening colonoscopy. METHODS: A cross-sectional study of 8916 men, who participated in a regular health-screening examination that included an H. pylori-specific immunoglobulin G antibody test and colonoscopy, was conducted to evaluate the association between H...
January 26, 2017: Helicobacter
https://www.readbyqxmd.com/read/28105616/-interpretation-of-the-updates-of-nccn-2017-version-1-0-guideline-for-colorectal-cancer
#19
Gong Chen
The NCCN has recently released its 2017 version 1.0 guideline for colorectal cancer. There are several updates from this new version guideline which are believed to change the current clinical practice. Update one, low-dose aspirin is recommended for patients with colorectal cancer after colectomy for secondary chemoprevention. Update two, biological agents are removed from the neoadjuvant treatment regimen for resectable metastatic colorectal cancer (mCRC). This update is based on lack of evidence to support benefits of biological agents including bevacizumab and cetuximab in the neoadjuvant setting...
January 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28089842/curbing-tumorigenesis-and-malignant-progression-through-the-pharmacological-control-of-the-wound-healing-process
#20
REVIEW
Melania Dovizio, Angela Sacco, Paola Patrignani
The prevention of cancer development and its progression is an urgent unmet medical need. Novel knowledge on the biology of cancer has evidenced that genetic changes occurring within cancer cells contribute, but are not sufficient, for tumor promotion and progression. The results of clinical studies and experimental animal models have suggested pursuing new avenues for the prevention of cancer development in the early stages, by using drugs that modulate platelet responses and those interfering with the synthesis and action of the mediators of inflammation...
January 12, 2017: Vascular Pharmacology
keyword
keyword
30001
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"